EBS News and Press, Emergent Biosolutions Inc. From 05/11/23

2023-05-11 14:12:03 ET Following a meeting of its expert advisors, the World Health Organization announced Thursday that the monkeypox outbreak would no longer be regarded as a public health emergency of international concern (PHEIC). Monkeypox virus, currently known as mpox, led to a g...

GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ...

2023-05-10 19:34:02 ET Summary Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses. OTC Narcan can contribute significantly to combatti...

2023-05-10 17:56:52 ET Summary For the month, the Singular coverage list underperformed the S&P 500 Index and the Russell 2000 by (507) and (174) basis points, respectively. Since our 2004 inception, the Singular coverage list has outperformed the S&P 500 and Russell 2000 ...

2023-05-10 03:00:19 ET Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q1 2023 Earnings Call...

2023-05-09 22:40:23 ET Emergent BioSolutions Inc. (EBS) Q1 2023 Earnings Conference Call May 09, 2023 05:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Paul Williams - Senior Vice President, Products Business Rich Lindahl - ...

2023-05-09 16:21:12 ET Emergent Biosolutions press release ( NYSE: EBS ): Q1 GAAP EPS of -$3.65. Revenue of $165M (-46.3% Y/Y). Shares -0.41% . Net loss of $183M and adjusted EBITDA of negative $101M Guidance FY: Total Revenues $1,100M - $1,200M; Net Loss $...

Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M Updates FY 2023 guidance and provides initial Q2 2023 guidance GAITHERSBURG, Md., May 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) toda...

2023-04-20 12:45:47 ET Contract manufacturer Emergent BioSolutions ( NYSE: EBS ) announced Thursday that its recently approved over-the-counter (PTC) opioid overdose therapy Narcan would be priced at around $50 per carton. In March, when the FDA approved the nasal spray for OT...

GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second q...